NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MGTX

MeiraGTx Holdings plc

Jun 30 • 04:00PM ET

6.52

Dollar change -0.09
Percentage change -1.36	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT BLUE AGIO EPIX CLLS BNTX ADVM ALLO EDIT CRSP

| Held by: IWM IBB DWAS IWO VTWO VHT IWN IWC DFAS PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.31	Insider Own	32.78%	Shs Outstand	79.42M	Perf Week	3.33%
Market Cap	523.98M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	-0.54%	Shs Float	54.02M	Perf Month	21.64%
Enterprise Value	538.34M	PEG	-	EPS next Q	-0.47	Inst Own	51.26%	Short Float	6.79%	Perf Quarter	-11.05%
Income	-167.33M	P/S	15.18	EPS this Y	54.01%	Inst Trans	8.61%	Short Ratio	6.38	Perf Half Y	5.67%
Sales	34.51M	P/B	15.64	EPS next Y	74.97%	ROA	-62.76%	Short Interest	3.67M	Perf YTD	7.06%
Book/sh	0.42	P/C	7.88	EPS next 5Y	22.68%	ROE	-216.14%	52W High	8.75 -25.49%	Perf Year	54.87%
Cash/sh	0.83	P/FCF	-	EPS past 3/5Y	-5.50% -5.10%	ROIC	-151.18%	52W Low	3.85 69.35%	Perf 3Y	-15.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-4.07% 20.15%	Gross Margin	-9.55%	Volatility	5.34% 6.33%	Perf 5Y	-53.26%
Dividend TTM	-	EV/Sales	15.60	EPS Y/Y TTM	-80.71%	Oper. Margin	-460.87%	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.51	Sales Y/Y TTM	203.23%	Profit Margin	-484.90%	RSI (14)	57.32	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.53	EPS Q/Q	-58.54%	SMA20	3.76%	Beta	1.24	Target Price	27.50
Payout	-	Debt/Eq	2.44	Sales Q/Q	176.33%	SMA50	9.07%	Rel Volume	1.11	Prev Close	6.61
Employees	381	LT Debt/Eq	2.34	Earnings	May 13 BMO	SMA200	8.42%	Avg Volume	575.40K	Price	6.52
IPO	Jun 08, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-4.79% -56.62%	Trades		Volume	636,665	Change	-1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-31-24	Resumed	Chardan Capital Markets	Buy	$36
Oct-23-20	Initiated	RBC Capital Mkts	Outperform	$27
Sep-15-20	Resumed	BofA Securities	Buy	$20
Sep-03-19	Initiated	Piper Jaffray	Overweight	$40
Feb-27-19	Reiterated	Chardan Capital Markets	Buy	$30 → $40
Jul-03-18	Initiated	BofA/Merrill	Buy
Jul-03-18	Initiated	Barclays	Overweight

Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
May-13-25 04:30PM	MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting (GlobeNewswire) -8.36% -10.00%
09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports First Quarter 2025 Financial and Operational Results (GlobeNewswire)
May-09-25 08:00AM	MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease (GlobeNewswire)
09:49AM	Loading…
Apr-10-25 09:49AM	Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? (Zacks) -5.59%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -9.14%
Mar-25-25 10:50AM	MeiraGTx Holdings: Gaining Regulatory Focus (SeekingAlpha)
09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-18-25 03:29AM	MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinsons Treatment (Insider Monkey)
Mar-14-25 08:27AM	MeiraGTx and Hologen launch AI-backed gene therapy venture (Pharmaceutical Technology) -5.58%
Mar-13-25 08:05AM	MeiraGTx spins Parkinsons, obesity gene therapies into AI startup (BioPharma Dive) +28.71%
08:00AM	MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
07:30AM	MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process (GlobeNewswire)
Feb-24-25 07:30AM	MeiraGTx seeks UK approval after gene therapy restores sight in children born blind (Pharmaceutical Technology)
06:30AM	Loading…
Feb-21-25 06:30AM	MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy (GlobeNewswire) +6.88%
Jan-22-25 08:30AM	MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations (GlobeNewswire) -5.77%
Jan-20-25 03:25PM	Is MeiraGTx Holdings plc (MGTX) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-29-24 06:19AM	MeiraGTx Holdings plc (MGTX): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-10-24 09:38AM	MeiraGTx granted RMAT designation by U.S. FDA to AAV2-hAQP1 (TipRanks)
Dec-09-24 08:00AM	MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire) +5.54%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-13-24 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.71%
08:00AM	MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
Oct-22-24 08:00AM	MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress (GlobeNewswire)
Oct-16-24 04:43PM	MeiraGTxs Parkinsons gene therapy shows promise in Phase I/II study (Clinical Trials Arena) +11.07%
07:30AM	MeiraGTx Holdings Reports Promising Parkinsons Therapy Results (TipRanks)
06:45AM	MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? (Zacks)
Oct-15-24 12:13PM	Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints (Benzinga) +14.87%
07:00AM	MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease (GlobeNewswire)
04:30PM	Loading…
Oct-09-24 04:30PM	MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference (GlobeNewswire)
Aug-30-24 09:46AM	Is MeiraGTx Holdings plc (MGTX) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-12-24 07:40AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.47%
07:05AM	MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results (GlobeNewswire)
07:03AM	MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi (GlobeNewswire)
May-24-24 09:57AM	Ireland the jewel in the life sciences crown? (Medical Device Network)
May-22-24 09:32AM	Jim Cramer is Recommending These Stocks (Insider Monkey)
May-10-24 03:09PM	MeiraGTx Holdings PLC Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-09-24 01:53PM	MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00AM	MeiraGTx Reports First Quarter 2024 Financial and Operational Results (GlobeNewswire)
Apr-24-24 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-18-24 04:30PM	MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference (GlobeNewswire)
Mar-14-24 10:31AM	MeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023 (GuruFocus.com) -7.09%
09:45AM	MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
08:30AM	MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
Feb-13-24 08:00AM	MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals (GlobeNewswire) -9.55%
Feb-01-24 07:30AM	Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors (PR Newswire)
Jan-10-24 09:55AM	Wall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Bet (Zacks)
08:49AM	MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Jan-02-24 12:17PM	MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why (Zacks)
Dec-25-23 09:55AM	Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade (Zacks)
Dec-21-23 07:07AM	J&J bets bigger on MeiraGTxs eye gene therapy (BioPharma Dive) +32.59%
07:00AM	MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million (GlobeNewswire)
Nov-21-23 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-14-23 07:21PM	MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress (GuruFocus.com)
08:00AM	MeiraGTx Announces Third Quarter 2023 Financial and Operational Results (GlobeNewswire)
Oct-31-23 08:00AM	BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions (News Direct)
Oct-30-23 08:25AM	Sanofi invests in MeiraGTx and its gene-regulating technology (BioPharma Dive) +20.27%
07:30AM	MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities (GlobeNewswire)
Oct-24-23 08:30AM	MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress (GlobeNewswire)
Aug-10-23 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Second Quarter 2023 Financial and Operational Results (GlobeNewswire)
Aug-01-23 09:10AM	MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology (GlobeNewswire)
Jul-19-23 08:30AM	MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing (GlobeNewswire) +8.04%
Jun-28-23 07:53PM	MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks) +8.20%
Jun-27-23 03:41PM	MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness (Benzinga) -7.31%
07:30AM	MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire)
Jun-22-23 04:01PM	MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Companys Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023 (GlobeNewswire)
Jun-16-23 10:00AM	MeiraGTx Holdings (NASDAQ:MGTX) shareholders have endured a 43% loss from investing in the stock three years ago (Simply Wall St.)
Jun-02-23 09:55AM	Does MeiraGTx Holdings PLC (MGTX) Have the Potential to Rally 320.9% as Wall Street Analysts Expect? (Zacks) +9.29%
May-17-23 09:55AM	Wall Street Analysts Predict a 314.29% Upside in MeiraGTx Holdings PLC (MGTX): Here's What You Should Know (Zacks) +10.00%
May-16-23 09:00AM	MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting (GlobeNewswire) +13.82%
May-11-23 08:00AM	MeiraGTx Reports First Quarter 2023 Financial and Operational Results (GlobeNewswire) -5.97%
May-03-23 08:30AM	MeiraGTx Announces $60 Million Private Placement of Ordinary Shares (GlobeNewswire) +12.52%
Apr-21-23 08:30AM	MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting (GlobeNewswire)
Apr-20-23 05:00PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-12-23 11:41AM	MeiraGTx Holdings plc (NASDAQ:MGTX) has caught the attention of institutional investors who hold a sizeable 31% stake (Simply Wall St.)
Mar-16-23 06:06AM	A Look At The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX) (Simply Wall St.)
Mar-14-23 08:00AM	MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results (GlobeNewswire)
Feb-13-23 03:00AM	JNJ Bought Up Biotech Stock MeiraGTx. It Sold Procept BioRobotics. (Barrons.com) +7.74%
Dec-13-22 01:56PM	MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms (Benzinga)
07:30AM	MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire)
06:26AM	MeiraGTx Holdings (NASDAQ:MGTX) investors are sitting on a loss of 71% if they invested three years ago (Simply Wall St.)
Dec-08-22 04:30PM	MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022 (GlobeNewswire)
Nov-22-22 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-16-22 06:02AM	MeiraGTx Holdings Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-11-22 10:02AM	Time To Worry? Analysts Are Downgrading Their MeiraGTx Holdings plc (NASDAQ:MGTX) Outlook (Simply Wall St.)
Nov-10-22 09:25AM	MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc. (GlobeNewswire)
Nov-03-22 10:48AM	Institutional investors own a significant stake of 35% in MeiraGTx Holdings plc (NASDAQ:MGTX) (Simply Wall St.)
Oct-04-22 08:00AM	MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress (GlobeNewswire) +9.25%
Oct-01-22 10:00AM	Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP) (GlobeNewswire)
Sep-16-22 02:00AM	MeiraGTxs Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government (GlobeNewswire)
Sep-08-22 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-22 09:45AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.71%
08:30AM	MeiraGTx Reports Second Quarter 2022 Financial and Operational Results (GlobeNewswire)
Aug-03-22 08:00AM	MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities (GlobeNewswire) +19.72%
Jun-28-22 02:28PM	MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial (Benzinga)
07:00AM	MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to Untreated Randomized Control (GlobeNewswire)
Jun-16-22 06:39AM	Further weakness as MeiraGTx Holdings (NASDAQ:MGTX) drops 13% this week, taking three-year losses to 67% (Simply Wall St.)

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on the development and manufacturing of genetic medicines to treat both inherited and more common conditions with severe unmet need. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Giroux Richard	CFO & COO	Apr 22 '25	Sale	6.00	24,000	144,000	882,494	Apr 22 08:54 PM
Richard Giroux	Officer	Apr 22 '25	Proposed Sale	6.00	24,000	144,000		Apr 22 08:52 PM
Forbes Alexandria	PRESIDENT & CEO	Apr 08 '25	Sale	5.34	47,500	253,650	1,408,983	Apr 08 09:05 PM
Forbes Alexandria	President / CEO	Apr 08 '25	Proposed Sale	5.29	47,500	251,265		Apr 08 04:55 PM
Giroux Richard	CFO & COO	Jan 21 '25	Sale	6.29	24,000	150,960	849,947	Jan 21 09:17 PM
Giroux Richard	Officer	Jan 21 '25	Proposed Sale	6.41	24,000	153,840		Jan 21 08:58 PM
Forbes Alexandria	PRESIDENT & CEO	Jan 07 '25	Sale	6.47	35,839	231,878	1,395,102	Jan 10 09:07 PM
Forbes Alexandria	PRESIDENT & CEO	Jan 08 '25	Sale	6.30	11,661	73,464	1,383,441	Jan 10 09:07 PM
Forbes Alexandria	President / CEO	Jan 07 '25	Proposed Sale	6.34	47,500	301,150		Jan 07 09:15 PM
PERCEPTIVE ADVISORS LLC	Director	Aug 12 '24	Buy	4.00	1,250,000	5,000,000	12,531,103	Aug 14 06:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGTX

MeiraGTx Holdings plc

Upgrade your FINVIZ experience